Cardiac biomarkers in dialysis

Area of Science:

• Nephrology
• Cardiology
• Biomarker Research

Background:

• Cardiovascular disease (CVD) is the primary cause of mortality in patients undergoing dialysis, accounting for ~40% of deaths.
• Effective cardiovascular risk stratification is crucial for optimizing therapeutic interventions and reducing morbidity and mortality in this population.
• Biomarkers offer a promising avenue for early detection of cardiac injury and timely intervention.

Purpose of the Study:

• To review the current evidence on the utility of cardiac biomarkers in diagnosing myocardial injury.
• To discuss the role of cardiac biomarkers in monitoring the risk of major adverse cardiovascular events (MACE) in dialysis patients.

Main Methods:

• Literature review of studies investigating cardiac biomarkers in hemodialysis and peritoneal dialysis patients.
• Focus on established biomarkers (BNP, NT-proBNP, troponins) and emerging biomarkers (ST2, galectin-3).

Main Results:

• Established biomarkers like BNP, NT-proBNP, and troponins are validated predictors of mortality in dialysis patients.
• Emerging biomarkers, including ST2 and galectin-3, show potential for risk stratification in both general and dialysis populations.
• Cardiac biomarkers aid in the early diagnosis of myocardial injury and risk assessment for MACE.

Conclusions:

• Cardiac biomarkers are essential tools for managing cardiovascular risk in dialysis patients.
• Utilizing a panel of biomarkers may enhance the accuracy of risk stratification and guide clinical decision-making.
• Further research into novel biomarkers could improve cardiovascular outcomes in patients on dialysis.